Alkem Labs profits slip 14% despite strong revenue growth in Q2

Alkem Laboratories, one of India's leading pharmaceutical manufacturers, posted mixed financial results for the quarter ended September 30, with profitability coming under pressure despite robust top-line expansion.

The company's net profit contracted to ₹667 crore in Q2, compared to ₹779 crore in the same period last year, reflecting a 14.37% decline. However, revenue from operations climbed to ₹4,552 crore, up 13.8% year-on-year, underscoring sustained demand for the company's product portfolio.

The divergence between revenue growth and profit decline signals rising cost pressures impacting the manufacturer's bottom line. Operating expenses, including raw material costs, employee compensation, and manufacturing overheads, expanded faster than sales during the quarter, compressing margins.

The results come at a time when India's pharmaceutical sector faces headwinds from elevated input costs and competitive pricing pressures in domestic and export markets. Despite the quarterly challenges, Alkem's ability to grow revenues indicates steady market traction across its therapeutic segments and geographic footprint.